MAP2K2 and cancer: Moreover, CDK4, EGFR, and MAP2K2 exhibited moderately high expression levels in cancer cells, with drugs targeting such therapeutic molecules presenting encouraging results in cancer therapy, but their clinical applications in kidney cancer are rarely reported [55–57].